Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris - Wikidata - wikimedia - TriplyDB

Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris

Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris

http://www.wikidata.org/entity/Q33757065

about

Promising new treatments for psoriasis Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease Immunology of psoriasis New era of biologic therapeutics in atopic dermatitis Putting together the psoriasis puzzle: an update on developing targeted therapies IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis A biophysical model of cell adhesion mediated by immunoadhesin drugs and antibodies Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis Post-therapeutic relapse of psoriasis after CD11a blockade is associated with T cells and inflammatory myeloid DCs Computational drug repositioning for peripheral arterial disease: prediction of anti-inflammatory and pro-angiogenic therapeutics.Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges.Type I interferon: potential therapeutic target for psoriasis?Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept.Targeting of human interleukin-12B by small hairpin RNAs in xenografted psoriatic skin.The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm.Inflammatory skin disease in K5.hTGF-beta1 transgenic mice is not dependent on the IL-23/Th17 inflammatory pathway.Human keratinocytes' response to injury upregulates CCL20 and other genes linking innate and adaptive immunity Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis.Redox imbalance in T cell-mediated skin diseases.A subpopulation of CD163-positive macrophages is classically activated in psoriasis.Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression.The pathophysiological role of dendritic cell subsets in psoriasis.Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)Resolved psoriasis lesions retain expression of a subset of disease-related genes Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates Cutaneous denervation of psoriasiform mouse skin improves acanthosis and inflammation in a sensory neuropeptide-dependent manner.Suppression of molecular inflammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skin inflammation.Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities.IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.Getting under the skin: the immunogenetics of psoriasis.Dendritic cell activation and memory cell development are impaired among mice administered medroxyprogesterone acetate prior to mucosal herpes simplex virus type 1 infection Alefacept: an expert review concerning the treatment of psoriasis.Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses.Alefacept: a safety profile.Update on psoriasis immunopathogenesis and targeted immunotherapy.

P2860

Q24598008-4C4A3989-F685-47DF-A3A5-D27C7BC56A41 Q26822421-15E0D26C-BEA1-44E6-A980-DDC4C6BFABE3 Q26822941-4D5F796C-74F0-49EF-B7E8-506DDF32AA94 Q26995800-ECE60270-0AAE-4A75-9110-DFC03F721AF8 Q27001941-1F53969C-FD93-43D8-825F-C2C260C473B3 Q27026785-4CF8B307-F225-49FF-8BC0-5366327B1C91 Q28268370-56402E67-CAF2-457A-97DC-466B4CB77AF6 Q28478230-BC286A8F-E22D-4984-963D-357965A323A7 Q28482161-FCC89C1A-2277-48BC-BBB6-BCF68B0FB217 Q28732143-E0F72B93-35C1-49E4-85AE-8D2349230CE6 Q30278668-8C8D5A8B-5D76-43D0-A30D-B4AF884906C4 Q33224048-0BEF0DC8-AC31-4231-9908-BE4D13F19989 Q33354097-E7E4D777-DBDA-4C34-826C-1681E2222890 Q33530942-000C4592-5502-4F12-902C-ABE66709EB42 Q33830208-2192797B-D853-445C-BB1C-FAB31C16DB91 Q33890805-1C9BE9AB-D273-4263-903A-B36AAE8C5C2B Q33911969-E3D809F7-B3B5-48D0-8C84-1C2BCBBD59A7 Q34006908-49963BEF-0351-4D30-A343-6734B7D5ACF7 Q34021856-C647C5CF-A46C-4706-AFB9-861C3F2FCCCD Q34089304-A369EB0D-6CC4-48DA-9BFC-2EB2AC9FE83D Q34130103-B5236081-642D-49CB-82C3-2E1D2F29C0E2 Q34149246-45D59FEF-5DE7-4A1C-99DA-F82E77E55D05 Q34180103-97B1361C-310C-4DFD-B0BE-CAC5C2C77A82 Q34200331-02617B84-B5CB-4601-8FDD-A9E1E5C3A7DA Q34245272-CB8DC9D6-4B16-41B9-9605-67C959964499 Q34490905-8CD8C88E-5A84-4FB8-85AE-B4AF36EAE219 Q34991139-069BE26C-4AE1-4AEE-B5B6-5DC1A336D299 Q35048297-CC9A816C-732B-4BB7-B5A2-FA0B595A4A39 Q35081002-C84429BA-2040-4ADA-8AEC-BE77A7519DC7 Q35084580-A3CE2600-DECD-4BBF-9302-D71C5C2BCFE2 Q35108924-3A631047-EBF5-4089-8373-9EFAEE8314AE Q35868862-20AE3ED5-3C52-4863-BCB6-1CC9E1EEF87C Q35906771-24EB4B6E-8B00-4BC0-B273-2E3F600AF95C Q36216535-DB9B155A-6803-4D75-8EFD-145EE89D12E8 Q36247085-7653EB25-4C29-45E0-850C-437F35BDB616 Q36252465-13FE1151-E786-4F3E-B989-46934EE67A00 Q36283748-50A6FE2A-55D5-4C38-9DFE-CEDF8ABEE829 Q36294340-D68C2964-9A3C-496E-BD26-DD66821397AA Q36299958-2387F49A-8416-4AD7-BF13-950E44FB4C59 Q36445919-8A8089FA-EFBF-4B6A-83C5-C4729D034AB9

P2860

Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris

http://www.wikidata.org/entity/Q33757065

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Alefacept reduces infiltrating ...... ry genes in psoriasis vulgaris

@ast

Alefacept reduces infiltrating ...... ry genes in psoriasis vulgaris

@en

type

label

Alefacept reduces infiltrating ...... ry genes in psoriasis vulgaris

@ast

Alefacept reduces infiltrating ...... ry genes in psoriasis vulgaris

@en

prefLabel

Alefacept reduces infiltrating ...... ry genes in psoriasis vulgaris

@ast

Alefacept reduces infiltrating ...... ry genes in psoriasis vulgaris

@en

P1433

Q33757065-B06ECECB-0857-4888-8691-2FC1D879CB3D

P1476

Q33757065-7B53BE84-51CE-4BE4-9D43-13C2823A8F70

P2093

Q33757065-0A4A936E-8D4D-4671-984C-2D724E6550C6

Q33757065-20037717-B838-4C9E-810D-C9A18183DE36

Q33757065-5D95D6BE-7D1E-446A-AD1F-AF5F51067966

Q33757065-5EE63276-9412-46B3-8A09-F8093AF35B30

Q33757065-6F35AAF5-A879-4FBF-A07A-AE2B73BA6455

Q33757065-AA7A935B-D003-4125-9D2B-79DA61DB0707

Q33757065-BD2236BD-5054-467C-A754-BD1D37EEE321

Q33757065-DC72B9F8-616E-4D40-AC1C-721A545DF0DB

Q33757065-E0BA5B45-E6B4-4438-A38C-77AA5A8BC629

Q33757065-EF399A03-B6F8-44AC-839D-561953E2C8CC

P2860

Q33757065-008F229F-06FC-4BF8-9440-66C6F19976AC

Q33757065-11A3017C-41D1-4436-94D2-D2FCBAD2E8F8

Q33757065-11FEE97F-3049-4BEB-8BDD-E4E08DE49D62

Q33757065-2304B828-09AB-4CA9-91F1-6896A347BD47

Q33757065-28FB0701-C778-4328-BAFB-FD0D5C7601B6

Q33757065-2C927042-1904-481A-AC87-84102890D4C7

Q33757065-451D1535-CA76-4EC2-91D2-33EDAF363206

Q33757065-4ADA70D6-58C2-46F6-89EB-F80D7F064F91

Q33757065-53504645-A9D2-4697-9671-63AFC6BFA247

Q33757065-5DA023F7-992C-4572-A24F-D5AD2214D474

P304

Q33757065-D6E3778F-C537-4E1A-B8CF-F3FCE74C8FE6

P31

Q33757065-F1DBCB48-6A9A-4F81-B167-1829098A962F

P356

Q33757065-660D59E5-DE30-4B52-9FC0-260B12AB224A

P407

Q33757065-1AB7DD31-3F21-491B-99AE-828438B642BE

P433

Q33757065-A81617BB-2F38-41BE-88CE-B9E7665D534B

P478

Q33757065-32428B6E-341A-4F3C-9CE3-E6D29F3A118F

P50

Q33757065-B82FACEF-3880-41D3-BEE7-ACCB6FCDB1E6

P577

Q33757065-6BFF1461-BB8D-4D84-8F36-DC44E96DAFB4

P5875

Q33757065-5417474C-7352-4A7B-BC9A-6A232348425D

P698

Q33757065-CF201934-0B9A-4A61-8B5B-5C1F9406F7FE

P932

Q33757065-479736E9-C66A-4291-9EEE-6A5C01014C4B

P356

PNAS.0409569102

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Alefacept reduces infiltrating ...... ry genes in psoriasis vulgaris

@en

P2093

Artemis Khatcherian

http://www.w3.org/2001/XMLSchema#string

Edmund Lee

http://www.w3.org/2001/XMLSchema#string

Francesca Chamian

http://www.w3.org/2001/XMLSchema#string

Inna Novitskaya

http://www.w3.org/2001/XMLSchema#string

Irma Cardinale

http://www.w3.org/2001/XMLSchema#string

James G Krueger

http://www.w3.org/2001/XMLSchema#string

Knut M Wittkowski

http://www.w3.org/2001/XMLSchema#string

Mary Sullivan-Whalen

http://www.w3.org/2001/XMLSchema#string

Patricia Gilleaudeau

http://www.w3.org/2001/XMLSchema#string

Shao-Lee Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Differentiation of regulatory T cells 1 is induced by CD2 costimulation

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris

Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-gamma production

The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3

Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro.

The immunologic basis for the treatment of psoriasis with new biologic agents.

The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiat

Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression.

CD8+ T cells in psoriatic lesions preferentially use T-cell receptor V beta 3 and/or V beta 13.1 genes.

Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha

P304

2075-2080

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0409569102

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

Michelle A Lowes

P577

2005-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8060996

http://www.w3.org/2001/XMLSchema#string

P698

15671179

http://www.w3.org/2001/XMLSchema#string

P932

545584

http://www.w3.org/2001/XMLSchema#string